According to the global anti-venom market report by IMARC Group, the market reached a value of US$ 1,023.40 Million in 2021, and it is projected to reach a value of US$ 1,544.40 Million by 2027, exhibiting a CAGR of 6.80% during 2022-2027.
Anti-venoms refer to purified antibodies that stop snake venom from binding to tissues and causing severe blood-clotting, allergic reactions, muscle injury, or nervous system problems. They are obtained from various animal species, such as funnel-web spiders, stonefish, snakes, redback spiders, box jellyfish, etc., using several technologies. The type of anti-venoms used generally depends on the history and examination of the patient and geographic, clinical, and pathologic factors. These antibodies prevent or reverse the snakebite envenoming effects, which aids in minimizing mortality and morbidity. As a result, anti-venoms find widespread applications in hospitals, clinics, medical, and ambulatory surgical centers.
Request a Free PDF Sample for more detailed market insights: https://www.imarcgroup.com/anti-venom-market/requestsample
Anti-Venom Market Trends and Drivers:
The escalating demand for safe, effective, and affordable antibodies, on account of the risk of snakebite envenoming, especially in the rural areas, causing occupational injury among agricultural workers and hunters, is primarily driving the anti-venom market.
Besides this, sleeping on the floor and open-plan housing, particularly in tropical regions, can expose people to bites from highly venomous and nocturnal snakes, which is further augmenting the market growth. Apart from this, the elevating prevalence of health problems, including paralysis that prevents breathing, bleeding disorders, kidney failure, severe local tissue destruction that can cause permanent disability, limb amputation, etc., is also catalyzing the global market.
Moreover, the introduction of detection kits with rapid enzyme immunoassay to identify snake poison in samples from urine, bite sites, plasma, blood, tissues, and body fluids is expected to bolster the anti-venom market in the coming years.
Ask Analyst for Customization and Explore Full Report with TOC & List of Figure: https://www.imarcgroup.com/anti-venom-market
Global Anti-Venom Market 2022-2027 Analysis and Segmentation:
The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.
Bharat Serums and Vaccines Limited (BSV), Boehringer Ingelheim International GmbH, Boston Scientific Corporation, CSL Limited, Haffkine Bio-Pharmaceutical Corporation Limited, Incepta Pharmaceuticals Limited, Merck & Co. Inc., Merck KGaA, MicroPharm Limited, Pfizer Inc. and Rare Disease Therapeutics Inc.
The report has segmented the market on the basis of region, species, anti-venom type, mode of action and end user.
Breakup by Species:
Breakup by Anti-venom Type:
- Polyvalent Anti-venom
- Monovalent Anti-venom
Breakup by Mode of Action:
Breakup by End User:
- Ambulatory Surgical Centers
Breakup by Region:
- North America: (United States, Canada)
- Asia Pacific: (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe: (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America: (Brazil, Mexico, Others)
- Middle East and Africa
If you want latest primary and secondary data (2022-2027) with Cost Module, Business Strategy, Distribution Channel, etc. Click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours of receiving full payment.
Key highlights of the report:
- Market Performance (2016-2021)
- Market Outlook (2022- 2027)
- Porter’s Five Forces Analysis
- Market Drivers and Success Factors
- SWOT Analysis
- Value Chain
- Comprehensive Mapping of the Competitive Landscape
If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
IMARC Services Private Limited.
134 N 4th St.
Brooklyn, NY 11249, USA
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800